Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.

Clinical lymphoma, myeloma & leukemia - 1 Apr 2022

Fang Kun, Qi Jiaqian, Zhou Meng, Zhang Ziyan, Han Yue

Abstract excerpt

TP53 gene mutations are common in myelodysplastic syndromes (MDS). Previous studies have reported their detrimental effects on patient survival. However, current treatment strategies mainly based on hypomethylating agent therapy (HMA) and hematopoietic stem cell transplantation (HSCT) still leave a lot to be desired. And there is also a lack of studies on large sample with a view to the refinement of specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 34690091
DOI: 10.1016/j.clml.2021.09.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Characteristics, Prognosis, and Treatment Strategies of TP53 Mutations in Myelodysplastic Syndromes.PMID 34690091Read ↗

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Current Guidelines, Therapies, and Future Considerations.Semantic proximity Read ↗

Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.Semantic proximity Read ↗

Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.Semantic proximity Read ↗

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.Semantic proximity Read ↗

Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.Semantic proximity Read ↗

Targeting TP53 Mutations in Myelodysplastic Syndromes.Semantic proximity Read ↗

[Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].Semantic proximity Read ↗

TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.Semantic proximity Read ↗

Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.Semantic proximity Read ↗

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions.Semantic proximity Read ↗

TP53 Mutation in Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.